1
Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., ... & Zhang, Y. (2023). Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. The Lancet, 401(10370), 49-59.
2
Estephan, L., Lin, Y. C., Lin, Y. T., Chen, Y. H., Pan, S. C., Hsieh, S. M., ... & Lien, C. E. (2023). Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial. Vaccine, 41(23), 3497-3505.
3
Zhou, C., Tang, K. J., Cho, B. C., Liu, B., Paz-Ares, L., Cheng, S., ... & Girard, N. (2023). Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. New England Journal of Medicine, 389(22), 2039-2051.
4
Tsai, H. L., Lin, C. C., Sung, Y. C., Chen, S. H., Chen, L. T., Jiang, J. K., & Wang, J. Y. (2023). The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study. British Journal of Cancer, 129(6), 947-955.
5
Huang, C. W., Hu, H. M., Hsu, W. H., Chen, C. Y., Huang, M. Y., Chen, C. P., ... & Wang, J. Y. (2023). A phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with radiotherapy and chemotherapy in patients with rectal cancer. Nanomedicine, 18(6), 511-524.
6
Tsai, H. L., Shi, H. Y., Chen, Y. C., Huang, C. W., Su, W. C., Chang, T. K., ... & Wang, J. Y. (2023). Clinical and cost-effectiveness analysis of mFOLOFX6 with or without a targeted drug among patients with metastatic colorectal cancer: inverse probability of treatment weighting. American Journal of Cancer Research, 13(9), 4039.
7
Tsai, H. L., Shi, H. Y., Chen, Y. C., Huang, C. W., Su, W. C., Chang, T. K., ... & Wang, J. Y. (2023). Clinical and cost-effectiveness analysis of mFOLOFX6 with or without a targeted drug among patients with metastatic colorectal cancer: inverse probability of treatment weighting. American Journal of Cancer Research, 13(9), 4039.
8
Chiang, N. J., & Chen, L. T. (2023). Adjuvant therapy in biliary tract cancers: oral fluoropyrimidine as a beginning. The Lancet, 401(10372), 170-171.
9
Hsieh, C. C., Su, Y. C., Jiang, K. Y., Ito, T., Li, T. W., Kaku-Ito, Y., ... & Shen, C. H. (2023). TRPM1 promotes tumor progression in acral melanoma by activating the Ca2+/CaMKIIδ/AKT pathway. Journal of Advanced Research, 43, 45-57.
10
Wong, Y. J., Tran, S., Huang, C. F., Hsu, Y. C., Preda, C., Toyoda, H., ... & Nguyen, M. H. (2023). Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study. Hepatology International, 1-12.
